Cyclacel Pharmaceuticals Inc. has announced that it has regained compliance with the Nasdaq Stock Market's Minimum Bid Price Requirement. The biopharmaceutical company, known for developing innovative cancer medicines, received a Compliance Notice from Nasdaq on June 3, 2025, confirming that the company has met the necessary criteria. Previously, on December 6, 2024, Cyclacel was notified that its shares had failed to maintain the minimum bid price of $1.00 for 30 consecutive business days. However, from May 12 to June 2, 2025, the closing bid price of Cyclacel's shares consistently exceeded $1.00, enabling the company to meet the requirement and resolve the issue.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.